



PARP9 Polyclonal Antibody

Catalog No	YP-Ab-07188
Isotype	IgG
Reactivity	Human;Mouse
Applications	WB;ELISA
Gene Name	PARP9 BAL
Immunogen	Synthesized peptide derived from human protein . at AA range: 450-530
Specificity	PARP9 Polyclonal Antibody detects endogenous levels of protein.
Formulation	Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
Source	Polyclonal, Rabbit,IgG
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Dilution	WB 1:500-2000 ELISA 1:5000-20000
Concentration	1 mg/ml
Purity	≥90%
Storage Stability	-20°C/1 year
Synonyms	ADP-ribosyltransferase diphtheria toxin-like 9;ARTD9;BAL;BAL1;EC:2.4.2.-; PARP9;PARP9 BAL;Poly [ADP-ribose] polymerase 9 (PARP-9) (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 9) (ARTD9) (B aggressive lymphoma protein)
Observed Band	88 kDa
Calculated Molecular Weight	819 aa, 92 kDa
Cell Pathway	Cytoplasm, cytosol . Nucleus . Shuttles between the nucleus and the cytosol (PubMed:16809771). Translocates to the nucleus in response to IFNG or IFNB1 stimulation (PubMed:26479788). Export to the cytosol depends on the interaction with DTX3L (PubMed:16809771). Localizes at sites of DNA damage in a PARP1-dependent manner (PubMed:23230272, PubMed:28525742). .
Tissue Specificity	Expressed in lymphocyte-rich tissues, spleen, lymph nodes, peripheral blood lymphocytes and colonic mucosa (PubMed:11110709, PubMed:16809771). Expressed in macrophages (PubMed:27796300). Also expressed in nonhematopoietic tissues such as heart and skeletal muscle (PubMed:11110709, PubMed:16809771). Isoform 2 is the predominant form (PubMed:11110709). Most abundantly expressed in lymphomas with a brisk host inflammatory response (PubMed:11110709, PubMed:16809771). In diffuse large B-cell lymphomas tumors, expressed specifically by malignant B-cells



(PubMed:11110709, PubMed:16809771).

Function	catalytic activity:NAD(+) + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.,miscellaneous:Overexpressed at significantly higher levels in fatal high-risk diffuse large B-cell lymphomas (DLB-CL) compared to cured low-risk tumors. Overexpression in B-cell lymphoma transfectants may promote malignant B-cell migration.,similarity:Contains 1 PARP catalytic domain.,similarity:Contains 2 Macro domains.,subunit:Interacts with BBAP.,tissue specificity:Expressed in lymphocyte-rich tissues, spleen, lymph nodes, peripheral blood lymphocytes and colonic mucosa. Also expressed in nonhematopoietic tissues such as heart and skeletal muscle. Isoform 2 is the predominant form.,
Background	catalytic activity:NAD(+) + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.,miscellaneous:Overexpressed at significantly higher levels in fatal high-risk diffuse large B-cell lymphomas (DLB-CL) compared to cured low-risk tumors. Overexpression in B-cell lymphoma transfectants may promote malignant B-cell migration.,similarity:Contains 1 PARP catalytic domain.,similarity:Contains 2 Macro domains.,subunit:Interacts with BBAP.,tissue specificity:Expressed in lymphocyte-rich tissues, spleen, lymph nodes, peripheral blood lymphocytes and colonic mucosa. Also expressed in nonhematopoietic tissues such as heart and skeletal muscle. Isoform 2 is the predominant form.,
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images